Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724028 | 0.89 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL1940437 | 0.86 | PTGDR2 (0.79) | PTGDR2 | |
| SCHEMBL2925164 | 0.84 | PTGDR2 (0.56) | PTGDR2MAPK8 | |
| SCHEMBL2922859 | 0.83 | PTGDR2 (0.57) | PTGDR2MAPK8 | |
| SCHEMBL1939847 | 0.79 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL1940304 | 0.78 | PTGDR2 (0.80) | PTGDR2MAPK8 | |
| SCHEMBL1940020 | 0.77 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL1940778 | 0.77 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL21913728 | 0.76 | PTGDR2 (0.72) | PTGDR2 | |
| SCHEMBL1940811 | 0.75 | PTGDR2 (0.78) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960398-B1 | ARYL ACETIC ACID AND ESTER DERIVATIVES AND THEIR USES AS ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20080312229-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1960398-A1 | ARYL ACETIC ACID AND ESTER DERIVATIVES AND THEIR USES AS ANTIINFLAMMATORY | Novartis AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065683-A1 | ARYL ACETIC ACID AND ESTER DERIVATIVES AND THEIR USES AS ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312229-A1 | Organic Compounds | DRD4, DRD1, SLC10A6 | PTGDR2 791/4885MAPK8 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.